血清可溶性晚期糖基化终末产物受体表达水平与肺癌的相关性

Correlation between the expression of soluble receptor for advanced glycation-end products in sera and lung cancer

目的:初步探讨血清可溶性晚期糖基化终末产物受体(sRAGE)表达水平与肺癌的相关性。方法 :应用双抗体夹心ELISA法检测血清sRAGE水平,并比较分析其在40例肺癌患者与40例健康对照者、20例肺腺癌患者与20例其他病理类型肺癌患者、18例TNM分期M0肺癌患者与22例M1肺癌患者间的水平差异。结果:肺癌患者与健康对照者的血清sRAGE水平分别为(226±220)和(160±136)ng/L;肺腺癌患者与其他病理类型肺癌患者的血清sRAGE水平分别为(125±87)和(194±166)ng/L;TNM分期M0肺癌患者与M1肺癌患者的血清sRAGE水平分别为(198±174)和(128±85)ng/L。经总体方差不等的均数比较近似t检验,结果显示3组人群的血清sRAGE水平差异均无显著性。结论:血清sRAGE表达水平个体差异大,其表达水平与肺癌是否相关尚须大样本量进一步证实。

Objective To study the association between the expressions of soluble receptor for advanced glycation-end products （sRAGE） in sera and lung cancer. Methods The expressions of sRAGE in sera in 40 patients with lung cancer （20 cases with lung adenocarcinoma and 20 cases with other types of lung cancer; 18 cases with lung cancer in M0 stage and 22 in M1 stage） and in 20 healthy controls were detected by ELISA of double antibody sandwich. Results The expressions of sRAGE in patients with lung cancer and healthy controls were （226 ± 220） ng/L and （160 ± 136） ng/L, respectively （P 〉 0.05） ; Those in patients with lung adenoearcinoma or other types of lung cancer were （ 125 ± 87） ng/L and （ 194 ± 166） ng/L, respectively （P 〉 0.05） ; And those in patients with lung cancer in M0 stage or M1 stage were （198 ± 174） ng/L and （128 ± 85） ng/L, respectively （P 〉 0.05）. Conclusion The correlation between the expression of RAGE in sera and lung cancer is not yet clear so that a further study with enlarged samples should be suggested.